Response and Survival with Dacarbazine and Vemurafenib for the Treatment of BRAFV600E-Mutated Melanoma and Dacarbazine and Ipilimumab for the First-Line Treatment of Advanced-Stage Melanoma


Response and Survival with Dacarbazine and Vemurafenib for the Treatment of BRAFV600E-Mutated Melanoma and Dacarbazine and Ipilimumab for the First-Line Treatment of Advanced-Stage Melanoma
Slides from presentations at ASCO 2011 and comments from Keith T Flaherty, MD and Jeffrey Weber, MD

Robert C et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364(26):2517-26. Abstract

Wolchok JD et al. Phase III randomized study of ipilimumab (IPI) plus dacarbazine (DTIC) versus DTIC alone as first-line treatment in patients with unresectable stage III or IV melanoma. Proc ASCO 2011;Abstract LBA5.

Dr Weber is Senior Member at H Lee Moffitt Cancer Center and Director of the Donald A Adam Comprehensive Melanoma Research Center in Tampa, Florida.